Skip to main content
. 2021 Jun 16;39(24):2698–2709. doi: 10.1200/JCO.20.03661

FIG 2.

FIG 2.

Patients with advanced cancer receiving germline genotype–directed therapy. (A) Bar graph demonstrates the 710 patients with metastatic or recurrent cancer harboring level 1 and level 3B LP/P germline variants and the percentage of these patients who received germline genotype–directed therapy by gene(s) and according to OncoKB level of evidence. (B) Bar graph demonstrates the 348 patients with advanced cancer that harbors an LP/P germline alteration in BRCA1 or BRCA2 and the percentage of these patients receiving a PARP-I by tumor type and according to the OncoKB level of evidence assigned for that tumor type. An additional 31 advanced cancer patients with LP/P BRCA1/2 germline alterations with colorectal (12), lung (5), esophagus and gastroesophageal junction (4), sarcoma (3), kidney (2), appendix (1), brain (1), neuroblastoma (1), head and neck (1), and skin (1) cancers were also identified, with none of them receiving a PARP-I. CUP, cancer of unknown primary; GIST, gastrointestinal stromal tumor; LP/P, likely pathogenic or pathogenic; PARP-I, poly(ADP-ribose) polymerase inhibitor.